Research

Hormonal

Tirzepatide (5, 10, or 15 mg once weekly) provides significantly longer continuous time in glycaemic control (HbA1c <7.0% and ≤6.5%) and sustained body weight reduction (≥5%) compared to placebo, semaglutide 1 mg, and insulin therapies in patients with type 2 diabetes.

For patients with Type 2 Diabetes, tirzepatide (5, 10, or 15 mg once weekly) offers significantly longer periods of stable blood sugar (HbA1c <7.0%) and sustained weight loss (≥5%) compared to placebo, semaglutide 1 mg, and insulin therapies. This suggests that tirzepatide may provide more durable disease management with fewer hypoglycaemic events than insulin.

GoodSupportsHIGH confidence
In this post hoc analysis, people with T2D experienced substantially longer continuous time in glycaemic control and more sustained body weight reductions with tirzepatide versus placebo and active comparators.
Brandon K. Bergman et al. · Diabetes Obesity and Metabolism · 2025

Why this rating

Large-scale post hoc analysis of multiple Phase 3 RCTs (N=6246), though exploratory in nature.

Source

Time spent in glycaemic control with sustained body weight reduction with tirzepatide: A post hoc analysis of the <scp>SURPASS</scp> clinical trial programme

Brandon K. Bergman et al. · Diabetes Obesity and Metabolism · 2025

DOI 10.1111/dom.16337

rct · n=6246Cited 3×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →